AP NEWS

Global Neurodegenerative Diseases Therapeutics Market (2018-2022) to Register a CAGR of Approx 8% - ResearchAndMarkets.com

January 11, 2019

DUBLIN--(BUSINESS WIRE)--Jan 11, 2019--The “Global Neurodegenerative Diseases Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.

Increase in aging population to drive growth in the market

The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer’s and Parkinson’s disease.

Availability of highly sensitive diagnostic modalities

The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.

High failure rate of neurodegenerative drugs in clinical trials

There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.

Key Players

Allergan Biogen Novartis Teva Pharmaceutical

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY INDICATION

Segmentation by indication Comparison by indication Multiple sclerosis - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Alzheimer’s disease - Market size and forecast 2017-2022 Parkinson’s disease - Market size and forecast 2017-2022 Huntington’s disease - Market size and forecast 2017-2022 Market opportunity by indication

PART 09: MARKET SEGMENTATION BY DRUG CLASS

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Allergan Biogen Novartis Teva Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/kk6qqx/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005160/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/11/2019 07:14 AM/DISC: 01/11/2019 07:14 AM

http://www.businesswire.com/news/home/20190111005160/en

AP RADIO
Update hourly